Pharmaceuticals, Biotechnology and Life Sciences
Nicox has provided certain regulatory and clinical updates for NCX 4251, its novel ophthalmic suspension of fluticasone propionate nanocrystals being…
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…
Allergan has won FDA’s approval to sell its breast implants in US.
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.